ArticleScientific reports2026
Gut microbiota-dependent protection by Lactobacillus reuteri against renal injury in brain-dead rats.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Donation-after-brain-death (DBD) serves as a major source of kidney transplant donors, and brain death (BD) induces systemic inflammation and gut barrier disruption, leading to renal injury and compromised organ quality. While Lactobacillus reuteri (L. reuteri) demonstrates anti-inflammatory and immunomodulatory properties that maintain gut microbiota homeostasis. However, its role in protecting organs against BD-associated injury remains unclear. This study investigated BD-induced renal injury mechanisms linked to gut-kidney axis dysregulation and evaluated L. reuteri's protective effects through microbiota-immune interactions. BD triggered intestinal barrier dysfunction, elevating gut permeability and promoting translocation of endotoxin lipopolysaccharide (LPS) to kidneys, which activated the TLR4/MyD88/NF-κB pathway, driving proinflammatory cytokine release, neutrophil infiltration, and renal dysfunction. L. reuteri pretreatment attenuated these effects by remodeling gut microbiota-reducing Proteobacteria while enriching Bacteroidota-and enhancing tight junction integrity, thereby suppressing pro-inflammatory LPS leakage and accumulation to renal tubule. Mechanistically, the increase in Bacteroidota abundance correlated with the downregulation of renal TLR4/NF-κB signaling, a pattern that is hypothesized to be explained by putative competitive inhibition by LPS derived from Bacteroidota. Concurrently, L. reuteri induced the upregulation of CD25⁺ immune cell expression in ileal glands and promoted CXCL2 production in renal and intestinal tissues, which is associated with the establishment of a gut-kidney immune homeostasis network. L. reuteri mitigates BD-induced renal injury through dual mechanisms-structural modulation of microbiota-derived LPS and intestinal immune remodeling-providing a novel microbiota-targeted adjunctive strategy to enhance donor organ viability in transplantation medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.